Association between malignancy and topical use of pimecrolimus

JAMA Dermatology

Volumn 151, Issue 6, 2015, Pages 594-599

  Margolis, David J ^a   Abuabara, Katrina ^a   Hoffstad, Ole J ^a   Wan, Joy ^a   Raimondo, Denise ^b   Bilker, Warren B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VALEANT PHARMACEUTICALS INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIMECROLIMUS; IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; ARTICLE; ATOPIC DERMATITIS; BURKITT LYMPHOMA; CANCER EPIDEMIOLOGY; CANCER RISK; CAUCASIAN; CHILD; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE ASSOCIATION; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INFANT; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NEWBORN; ONSET AGE; OSTEOSARCOMA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RISK ASSESSMENT; STANDARDIZED INCIDENCE RATIO; TREATMENT DURATION; YOUNG ADULT; ANALOGS AND DERIVATIVES; CANCER REGISTRY; CUTANEOUS DRUG ADMINISTRATION; DERMATITIS, ATOPIC; LONGITUDINAL STUDY; NEOPLASMS; PATHOLOGY; PRESCHOOL CHILD; REGISTER; RISK;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DERMATITIS, ATOPIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; MALE; NEOPLASMS; REGISTRIES; RISK; SEER PROGRAM; TACROLIMUS;

EID: 84931058033     PISSN: 21686068     EISSN: 21686084     Source Type: Journal    
DOI: 10.1001/jamadermatol.2014.4305     Document Type: Article

References (21)

1. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis, section 1: diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338-351.
2. Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134(6):1527-1534.
3. Siegfried EC, Jaworski JC, Hebert AA. Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. Am J Clin Dermatol. 2013;14(3):163-178.
4. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348(17):1681-1691.
5. Clarke CA, Morton LM, Lynch C, et al. Risk of lymphoma subtypes after solid organ transplantation in the United States. Br J Cancer. 2013;109(1):280-288.
6. Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management, part I: epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol. 2011;65(2):253-261.
7. Tessari G, Girolomoni G. Nonmelanoma skin cancer in solid organ transplant recipients: update on epidemiology, risk factors, and management. Dermatol Surg. 2012;38(10):1622-1630.
8. Margolis DJ, Apter AJ, Gupta J, et al. The persistence of atopic dermatitis and filaggrin (FLG) mutations in a US longitudinal cohort. J Allergy Clin Immunol. 2012;130(4):912-917.
9. Kapoor R, Menon C, Hoffstad O, Bilker W, Leclerc P, Margolis DJ. The prevalence of atopic triad in children with physician-confirmed atopic dermatitis. J Am Acad Dermatol. 2008;58(1):68-73.
10. Kapoor R, Hoffstad O, Bilker W, Margolis DJ. The frequency and intensity of topical pimecrolimus treatment in children with physician-confirmed mild to moderate atopic dermatitis. Pediatr Dermatol. 2009;26(6):682-687.
11. Margolis JS, Abuabara K, Bilker W, Hoffstad O, Margolis DJ. Persistence of mild to moderate atopic dermatitis. JAMA Dermatol. 2014;150(6):593-600.
12. Williams HC, Burney PG, Hay RJ, et al. The U. K. Working Party's Diagnostic Criteria for Atopic Dermatitis, I: derivation of aminimum set of discriminators for atopic dermatitis. Br J Dermatol. 1994;131(3):383-396.
13. Fleiss JL, Levin B, PalkMC. StatisticalMethods for Rates and Proportions. 3rd ed. Hoboken, NJ: John Wiley & Sons; 2003.
14. Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am AcadDermatol. 2002;47(1):1-17.
15. Schneeweiss S, Doherty M, Zhu S, et al. Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma. Dermatology. 2009;219(1):7-21.
16. Arellano FM, Wentworth CE, Arana A, Fernández C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol. 2007;127(4):808-816.
17. Fonacier L, Spergel J, Charlesworth EN, et al; American College of Allergy, Asthma and Immunology; American Academy of Allergy, Asthma and Immunology. Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2005;115(6):1249-1253.
18. Boyle TJ, Coles RE, Kizilbash AM, Lyerly HK. Effects of cyclosporine on human B-cell lymphoma development in vivo. Surg Oncol. 1992;1(1):79-86.
19. Van Leent EJ, Ebelin ME, Burtin P, Dorobek B, Spuls PI, Bos JD. Low systemic exposure after repeated topical application of pimecrolimus (Elidel), SD Z ASM 981, in patients with atopic dermatitis. Dermatology. 2002;204(1):63-68.
20. Stiehm ER, Roberts RL, Kaplan MS, Corren J, Jaracz E, Rico MJ. Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointment. J Am Acad Dermatol. 2005;53(2) (suppl 2):S206-S213.
21. Papp KA, Breuer K, Meurer M, et al. Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interferewith the development of protective antibodies after vaccination. J Am Acad Dermatol. 2005;52(2):247-253.